ClinicalTrials.gg
Active, not recruitingNCT03408665STEREOLIVERUpdated Mar 30, 2026

Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

An interventional study of SBRT in Liver Cancer and Liver Metastases, sponsored by Centre Oscar Lambret. Active, not recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Centre Oscar Lambret · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Liver Neoplasms with a site in France — 16 open to participants now, 28 under way, 4 of them phase 3. Liver Neoplasms · France.

Enrollment
22nd of 66
280 · median 129
Started
2019
with 5 others
No phase
16 of 93
5 open now
Primary completion
2026-12
later than 14 of 27 live
Registered
54th of 93
by date
Lead sponsor
3 of 93
Centre Oscar Lambret

Among the 93 studies in Liver Neoplasms with a site in France, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2019, is one of 16 with no phase, reaches primary completion later than 14 of the 27 other live ones, and was the 54th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

16 of the 93 studies in Liver Neoplasms with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Liver Neoplasms with a site in France, or all of them as a file.
02

Study summary

Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to be treated by SBRT and unable to participate in another trial (non eligible patient or non included centers), can be included in this national study, in a prospective way.

Read the detailed description

Patients will first go through an inclusion check-up consisting of:

  • a clinical exam: disease history, previous treatments, weight, height, patient's performance status (ECOG) and HCC status.
  • a biological test: biochemical (total bilirubin, ASAT-ALAT, LDH, albumin, alkaline phosphatases, GGT), hematological (if the patient is going to receive a fiducial), alphafoetoprotein (for HCC) and pregnancy test (if applicable)
  • a tumor assessment: using a CT-scan or a MRI and using RECIST or mRECIST (if HCC), plus other morphological exams if judged useful by the investigator This check-up has to be realized within 28 days before inclusion. Then, the use of fiducial is optional.

Before the beginning of the treatment, a pre-therapeutic check-up is done:

  • the inclusion check-up has to be done a second time if the treatment begins more than 28 days after the first one
  • Tracking scanner.

The SBRT treatment is done in 3 to 6 times and no specific SBRT techniques are asked for, the investigator can choose according to the center habits.

After the treatment, a follow-up will be realized at 3, 6, 9, 12, 18, 24, 30 and 36 months and then once a year until the last patient included reach their 36th month of follow-up. The follow-up check-up consists of a clinical exam, biological test, tumor assessment and tolerance assessment.

03

Conditions studied

  • Liver Cancer
  • Liver Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • With primary or secondary liver tumor and matching one of the following situations:
  • Liver (LM): anatomopathologic diagnosis of the primary tumor
  • Hepatocellular Carcinoma (HCC): diagnosis achieved through or through non-invasive methods approved by AASLD criteria (Bruix, 2011)
  • Cholangiocarcinoma (CC): diagnosis achieved through biopsy
  • Other primitive hepatic tumor achieved through biopsy
  • Meet the requirements for SBRT treatment:
  • Liver Metastasis (LM): oligometastatic disease
  • Hepatocellular Carcinoma (HCC): non eligible lesion to curative surgery
  • Cholangiocarcinoma (CC): nodular lesion
  • Other primitive hepatic tumor: non eligible lesion to curative surgery
  • Able to receive a SBRT treatment according to the multidisciplinary consultation meeting
  • Tumor assessable with CT-scan or MRI according to in HCC or Recist 1.1 in other situations
  • Affiliation to the National Social Security System
  • With informed and signed consent

Exclusion criteria

Exclusion Criteria:

  • Eligibility to a curative surgery according to the multidisciplinary consultation meeting
  • to SBRT (especially Cirrhose Child C)
  • Pregnant or breastfeeding women
  • Patient Under guardianship or tutorship
  • Impossibility to submit at the study procedures due to geographic, social or mental reasons
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    SBRT

    Stereotaxic Body Radiation Therapy administred in 3 to 6 fractions.

    Radiation: SBRT

Interventions

  • RadiationSBRT

    3 sessions at least, up to 6. Neither specifc device is imposed.

06

What researchers measure

Primary outcomes

  1. SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis

    Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.

    Time frame: From baseline to 36 months following up.

Secondary outcomes

  1. Estimate the SBRT efficiency in a prospective way, in term of local progression-free survival (L-PFS) for patient treated with SBRT in the 4 considered clinical situations.

    Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.

    Time frame: From baseline to 36 months following up.

  2. Describe the different SBRT techniques used in the study for liver tumor.

    Description of SBRT techniques used.

    Time frame: From baseline to 36 months following up.

  3. Determine the SBRT feasibility by comparison of planned SBRT to performed SBRT.

    Description of reasons leading to SBRT scheme modification or interruption.

    Time frame: From baseline to 36 months following up.

  4. Estimate the SBRT efficiency in a prospective way, in term of overall survival (OS) in the 4 considered clinical situations.

    Overall survivall thanks to Kaplan-meier method, from registration date to date of death.

    Time frame: From baseline to 36 months following up.

  5. Estimate the SBRT efficiency in a prospective way, in term of progression-free survival (PFS) in the 4 considered clinical situations.

    Progression-free survival (PFS) thanks to Kaplan-Meier method from registration date to date of progressive disease.

    Time frame: From baseline to 36 months following up.

  6. Assess the immediate and delayed toxicity.

    Description of toxicity associated to SBRT or the fiducial use thanks to NCI-CTCAE v4.0.

    Time frame: From baseline to 36 months following up.

  7. Estimate the quality-adjusted survival (Q-TWiST) for patients in each of the 4 considered clinical situations.

    Q-TWIST consists in 3 clinical states: time in toxicity before progressive disease, time in progressive disease, time without toxicity nor progressive disease.

    Time frame: From baseline to 36 months following up.

  8. Estimate the proportion of patients for whom an hospitalization is required.

    during the treatment and until 3 months after and the cumulative duration of the hospitalization over those 3 months.

    Time frame: From baseline to 36 months following up.

  9. Estimate the impact of the different SBRT techniques on SBRT efficacy according to L-PFS.

    Estimation of impact of SBRT technique used on SBRT efficacy according to L-PFS.

    Time frame: From baseline to 36 months following up.

  10. Estimate the impact of the different SBRT techniques on SBRT efficacy according to PFS.

    Estimation of impact of SBRT technique used on SBRT efficacy according to PFS.

    Time frame: From baseline to 36 months following up.

  11. Estimate the impact of the different SBRT techniques on SBRT efficacy according to OS.

    Estimation of impact of SBRT technique used on SBRT efficacy according to OS.

    Time frame: From baseline to 36 months following up.

  12. Quality of life according to QLQ-C30 questionnaire

    QLQ-C30 will be filled at baseline, at the 3-months follow-up and at the 6-months follow-up.

    Time frame: From Baseline to the 6-months follow-up

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 92 months after the start.

Of 149 non-industry interventional studies with no phase under Liver Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 73. This study's planned 92 months is above that.

Counting every sponsor, half of 168 studies reached it within 39 months; a quarter within 18 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2018
First posted
Jan 24, 2018
StartActual
Mar 13, 2019
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jan 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03408665
Collaborators
Canceropôle Nord Ouest
Responsible party
Sponsor
First posted
Jan 24, 2018
Start date
Mar 13, 2019
Primary completion
Dec 1, 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Xavier MIRABEL, MD
principal investigator · Centre Oscar Lambret

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion